Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.

Helman E, Nguyen M, Karlovich CA, Despain D, Choquette AK, Spira AI, Yu HA, Camidge DR, Harding TC, Lanman RB, Simmons AD.

Clin Lung Cancer. 2018 Nov;19(6):518-530.e7. doi: 10.1016/j.cllc.2018.07.008. Epub 2018 Aug 7.

2.

Microfluidic-based sperm sorting & analysis for treatment of male infertility.

Samuel R, Feng H, Jafek A, Despain D, Jenkins T, Gale B.

Transl Androl Urol. 2018 Jul;7(Suppl 3):S336-S347. doi: 10.21037/tau.2018.05.08. Review.

3.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).

Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria JC, Solomon B, Camidge DR, Gadgeel S, Paweletz C, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee H.

Clin Cancer Res. 2016 May 15;22(10):2386-95. doi: 10.1158/1078-0432.CCR-15-1260. Epub 2016 Jan 8.

4.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.

N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.

5.

Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.

Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, Gillies H, Kawut SM.

Chest. 2013 Feb 1;143(2):315-323. doi: 10.1378/chest.12-0270.

6.

ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ; ARIES-3 Study Group.

Cardiovasc Ther. 2012 Apr;30(2):93-9. doi: 10.1111/j.1755-5922.2011.00279.x. Epub 2011 Jun 20.

PMID:
21884013
7.

Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.

Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C.

Am J Cardiol. 2011 Jul 15;108(2):302-7. doi: 10.1016/j.amjcard.2011.03.037. Epub 2011 May 3.

PMID:
21545989
8.

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.

Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ; ARIES Study Group.

J Am Coll Cardiol. 2009 Nov 17;54(21):1971-81. doi: 10.1016/j.jacc.2009.07.033.

9.

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ.

Chest. 2009 Jan;135(1):122-129. doi: 10.1378/chest.08-1028. Epub 2008 Sep 23.

PMID:
18812445
10.

Natalizumab induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group.

N Engl J Med. 2005 Nov 3;353(18):1912-25. Erratum in: N Engl J Med. 2015 May 21;372(21):2074.

Supplemental Content

Loading ...
Support Center